Allergen Immunotherapy (AIT) with Subcutaneous Immunotherapy (SCIT)

Subcutaneous allergen immunotherapy (SCIT) with aeroallergens is covered for patients with allergic rhinitis/conjunctivitis and/or allergic asthma when there is clinical symptom correlation with natural exposure and demonstrable specific IgE. Coverage requires failure or intolerance of pharmacotherapy/allergen avoidance (or patient preference) documented generally after at least a 28-day trial; initial maintenance therapy is typically 3–5 years with evaluation every 6–12 months, and therapy without clinical benefit may be discontinued and not reimbursed after two years.

"SCIT with aeroallergen preparations is covered for allergic rhinitis and/or allergic conjunctivitis (seasonal, perennial, or both)."

Sign up to see full coverage criteria, indications, and limitations.